Response to Magnesium and Vascular Dysfunction in Malignant Hypertension
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We are grateful to Van Laecke and Vanholder1 for their interesting observations and comments. We agree that molecular mechanisms of the persistent endothelial dysfunction in patients with malignant hypertension (MHT) observed in our study remain to be clarified, although this aspect was beyond the scope and aims of our published study because of the rarity of MHT as a condition.1
It is plausible that possible electrolyte abnormalities (including magnesium) and also subclinical renal dysfunction in MHT …